Abrahami, D. ., D’Andrea, E. ., Yin, H. ., Kim, S. C., Paik, J. M., Wexler, D. ., … Patorno, E. . (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
E. Patorno
First name
E.
Last name
Patorno
Suissa, K. ., Schneeweiss, S. ., Douros, A. ., Yin, H. ., Patorno, E. ., & Azoulay, L. . (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
Abrahami, D. ., Tesfaye, H. ., Yin, H. ., Vine, S. ., Hicks, B. ., H. Y. Yu, O. ., … Azoulay, L. . (2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
Pradhan, R. ., Patorno, E. ., Tesfaye, H. ., Schneeweiss, S. ., Yin, H. ., Franklin, J. ., … Azoulay, L. . (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021
Suissa, K. ., Schneeweiss, S. ., Douros, A. ., Filion, K. B., Yin, H. ., Patorno, E. ., & Azoulay, L. . (2021). The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes Obes Metab. http://doi.org/10.1111/dom.14494